Výsledky vyhledávání

Altered Expression of Matrix-Related Molecules in the Development of Chronic Thy1.1 Nephritis

Autor: Toshihiro Shinosaki, Masao Masui, Takayuki Kuroda, Mitsuru Notoya, Masashi Ito, Hideki Tanioka

Publikováno v: Nephron Experimental Nephrology. 104:e169-e182

Background/Aim: Matrix production and degradation are critically important in chronic nephritis. Our aim was to investigate the precise expression of matrix-related molecules which is essential for understanding the pathogenesis of renal disease. Met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1fcdcbd4d03f8248779d8ed6f88b82e
https://doi.org/10.1159/000096068

Zobrazit plný text záznamu

Hypotensive and Prophylactic Effects of Angiotensin II Subtype 1 Receptor Antagonist, Irbesartan, in Stroke‐Prone Spontaneously Hypertensive Rats

Autor: Mikinori Torii, Toshitake Shimamura, Masatoshi Nakajima, Masao Masui

Publikováno v: Clinical and Experimental Hypertension. 26:27-42

We determined the acute hypotensive effect of a single administration and the prophylactic effect of chronic treatment with Irbesartan, an angiotensin II receptor antagonist, on the development of end-organ damage in stroke-prone spontaneously hypert

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b1ab73e90210e1e39abaf624ac815a8
https://doi.org/10.1081/ceh-120027329

Zobrazit plný text záznamu

Plný text ve formátu HTML

Pharmacologic Characterization of S-1255, a Highly Potent and Orally Active Endothelin A Receptor Antagonist

Autor: Yoko Hayasaki-Kajiwara, Mitsuyoshi Ninomiya, Toshitake Shimamura, Takanori Iwasaki, Masatoshi Nakajima, Shin-ichi Mihara, Masafumi Fujimoto, Noriyuki Naya, Masao Masui, Masaru Kawakami

Publikováno v: Journal of Cardiovascular Pharmacology. 37:471-482

The pharmacologic properties of a novel nonpeptide endothelin (ET) receptor antagonist, S-1255 ([R]-[+]-2-[benzo(1,3)dioxol-5-yl]-6-isopropyl-4-[4-methoxyphenyl]-2H-chromene-3-carboxylic acid), was studied. [3H]S-1255 specifically bound to porcine ao

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e99b18d0ae7f35b76c7e845732fd41f
https://doi.org/10.1097/00005344-200104000-00014

Zobrazit plný text záznamu

Pharmacological Studies on a New Antihypertensive Agent, S-2150, a Benzothiazepine Derivative: 1. Antinecrotic and Antiarrhythmic Effects in Reperfused Rat Hearts

Autor: Yukio Takahara, Osamu Uno, Susumu Funakawa, Masao Masui, Kazuki Matsunaga, Shin-ichi Mihara, Kazumi Iwaki

Publikováno v: Journal of Cardiovascular Pharmacology. 28:526-532

S-2150 is a new 1,5-benzothiazepine derivative that inhibits [ 3 H]diltiazem and [ 3 H]WB4101 bindings to the membrane of rat tissue. The effects of S-2150 on ischemia/reperfusion injury were studied in anesthetized rats. S-2150 reduced the myocardia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68bfeddcb3b505caf64cc9c296b3d086
https://doi.org/10.1097/00005344-199610000-00008

Zobrazit plný text záznamu

Renoprotective action of a matrix metalloproteinase inhibitor in progressive mesangioproliferative nephritis

Autor: Mitsuru Notoya, Takayuki Kuroda, Eri Kanaoka, Hiroyuki Okamoto, Toshihiro Shinosaki, Yoshinori Tamura, Masao Masui, Masashi Ito

Publikováno v: Nephron Extra
Nephron Extra, Vol 2, Iss 1, Pp 133-146 (2012)

Background/Aim: Matrix metalloproteinases (MMPs) play pivotal roles in extracellular matrix turnover and are involved in chronic kidney disease. The renoprotective action of a synthetic MMP inhibitor, compound A, was investigated in chronic nephritis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2c9d90f02e606e6ae7bd3b75a9fcf7b
https://pubmed.ncbi.nlm.nih.gov/22739248

Zobrazit plný text záznamu

Pharmacological studies on a new dihydrothienopyridine calcium antagonist, S-312-d: Therapeutic effects of s-312-d on cerebral metabolic impairment in stroke-prone spontaneously hypertensive rats

Autor: Masao Masui, Kazuki Matsunaga, Motohiko Ueda

Publikováno v: Drug Development Research. 33:10-19

The therapeutic effects of S-312-d on cerebral metabolic impairment were investigated in the stroke-prone spontaneously hypertensive rats (SHRSP) with apparent stroke symptoms. S-312-d was orally administered 10 mg/kg/day (25 μmol/kg/day) to the SHR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7d3c7a7e80cc77fc902c79ce4f50f880
https://doi.org/10.1002/ddr.430330103

Zobrazit plný text záznamu

Prophylactic effects of novel dihydropyrazolopyridine (83-0256) and dihydrothienopyridine (83-0312, 83-0327) calcium antagonists in stroke-prone spontaneously hypertensive rats

Autor: Hiroyuki Ito, Masaru Kawakami, Seijiro Hara, Motohiko Ueda, Masatoshi Nakajima, Masao Masui

Publikováno v: Drug Development Research. 20:453-464

The prophylactic effects of several Ca antagonists against the incidence of cerebral stroke in stroke-prone spontaneously hypertensive rats (SHRSP) (9-17 weeks of age) fed a stroke-prone (SP) diet (Na, 0.39%) were investigated for 8 weeks. The contro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::be067650f7d41c95f1ee5b8a233394a5
https://doi.org/10.1002/ddr.430200405

Zobrazit plný text záznamu

Role of Endogenous Endothelin in the Development of Hypertension in Rats

Autor: Masaru Kawakami, Takuo Fujita, Masaaki Fukase, Masao Masui, Yasuyuki Takagi, Motohiko Ueda, Shoichiro Takata

Publikováno v: American Journal of Hypertension. 4:389-391

To further elucidate the pathophysiologic role of endogenous endothelin (ET), we have studied the chronic effect of anti-ET gamma-globulin on the development of hypertension in spontaneously hypertensive rats (SHR) and stroke prone SHR (SHR-SP) for t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d07f9dd7f5fbe52ed34605d40b7c83d
https://doi.org/10.1093/ajh/4.4.389

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání